Department of Medicine, University Health Network, Toronto, ON, Canada.
Clin Endocrinol (Oxf). 2012 Feb;76(2):264-71. doi: 10.1111/j.1365-2265.2011.04180.x.
Acromegaly results from increased growth hormone and its target insulin-like growth factor-1, most commonly due to a pituitary tumour. As it is frequently accompanied by infertility, little is known about the course of this disease in pregnancy.
We describe 13 new pregnancies in acromegalic women and compare their outcomes in a systematic review of the literature.
We collected clinical, biochemical, imaging, and outcomes data during and following pregnancy and performed a systematic review for a total of 47 pregnancies. An extended analysis of 106 pregnancies was also performed.
In 13 newly described cases, pregnancy was un-complicated without need for additional surgical intervention. In these pregnancies, adjunctive medical therapy was required in three patients. This was in the form of somatostatin analogs (SA) (3/13) as well as pegvisomant in 1/13 to control symptomatic and biochemical progression. One 37-year-old female succeeded in having two separate pregnancies 2 years apart both without need for any form of medical therapy. Review of an additional 34 published reports allowed for an analysis of outcomes in 47 pregnancies. Adjunctive medical therapy during pregnancy was required in 15 of these cases where 12 received SA and an additional three received dopamine agonists. None of these patients developed endocrine or neurologic complications during pregnancy. In an extended analysis of 106 pregnancies, treatment during pregnancy appears to be associated with good disease control but increased risk of microsomic or macrosomic newborns depending on the medical agent used.
In 13 newly described pregnancies along with systematic review of an additional 34 cases indicate that pregnancy in treated acromegalic women can proceed without significant complications or teratogenicity. Medical treatment during pregnancy with DA or SA appears to be associated with altered neonatal weight. Nevertheless, gestation may have a beneficial impact on acromegaly control both during and following pregnancy.
肢端肥大症是由生长激素及其靶胰岛素样生长因子-1 增加引起的,最常见的原因是垂体肿瘤。由于常伴有不孕,因此对妊娠期间该病的病程知之甚少。
我们描述了 13 例肢端肥大症女性的新妊娠,并在文献系统回顾中比较了她们的结局。
我们收集了妊娠期间和之后的临床、生化、影像学和结局数据,并对总共 47 例妊娠进行了系统回顾。还对 106 例妊娠进行了扩展分析。
在 13 例新描述的病例中,妊娠无并发症,无需额外手术干预。在这些妊娠中,有 3 例患者需要辅助药物治疗。其中 3 例使用生长抑素类似物 (SA),1 例使用培维索孟,以控制症状和生化进展。一位 37 岁的女性成功地在相隔 2 年的时间里进行了两次独立的妊娠,均无需任何形式的药物治疗。对另外 34 份已发表报告的回顾允许对 47 例妊娠的结局进行分析。在这些病例中,有 15 例需要在妊娠期间辅助药物治疗,其中 12 例接受了 SA,另有 3 例接受了多巴胺激动剂。这些患者在妊娠期间均未发生内分泌或神经并发症。在对 106 例妊娠的扩展分析中,妊娠期间的治疗似乎与良好的疾病控制相关,但根据所用药物的不同,新生儿可能会出现微小或巨大的风险。
在 13 例新描述的妊娠以及对另外 34 例病例的系统回顾中表明,患有肢端肥大症的女性可以在没有明显并发症或致畸性的情况下进行妊娠。在妊娠期间使用 DA 或 SA 进行治疗似乎与新生儿体重改变相关。然而,妊娠可能对妊娠期间和之后的肢端肥大症控制有有益的影响。